Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500944PMID: 30000003
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1211441-98-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of ribociclib during breastfeeding. Because protein binding of ribociclib is 70%, clinically important amounts of the drug might pass into breastmilk. The manufacturer recommends that breastfeeding be discontinued during ribociclib therapy and for at least 3 weeks after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Ribociclib
CAS Registry Number
1211441-98-3
Drug Class
- Breast Feeding
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Signal Transduction Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Binimetinib.[Drugs and Lactation Database (...]Review Binimetinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Osimertinib.[Drugs and Lactation Database (...]Review Osimertinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Acalabrutinib.[Drugs and Lactation Database (...]Review Acalabrutinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Glasdegib.[Drugs and Lactation Database (...]Review Glasdegib.. Drugs and Lactation Database (LactMed®). 2006
- Review Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.[Ann Pharmacother. 2019]Review Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.Rascon K, Flajc G, De Angelis C, Liu X, Trivedi MV, Ekinci E. Ann Pharmacother. 2019 May; 53(5):501-509. Epub 2018 Dec 7.
- Ribociclib - Drugs and Lactation Database (LactMed®)Ribociclib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...